{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:09:34Z","timestamp":1789841374602,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.pupt.2019.101840","type":"journal-article","created":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T06:09:18Z","timestamp":1568095758000},"page":"101840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Mycophenolate mofetil as an alternative treatment in sarcoidosis"],"prefix":"10.1016","volume":"58","author":[{"given":"Spyros","family":"Papiris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Stagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Papadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lykourgos","family":"Kolilekas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Korbila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Apollonatou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kallieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helias","family":"Gialafos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Chatziioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana I.","family":"Papaioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effrosyni D.","family":"Manali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pupt.2019.101840_bib1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1034\/j.1399-3003.1999.14d02.x","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. Sarcoidosis statement committee. American thoracic society. European respiratory society. World association for sarcoidosis and other granulomatous disorders","volume":"14","author":"Costabel","year":"1999","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.pupt.2019.101840_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1586\/eci.11.84","article-title":"Therapy for sarcoidosis: evidence-based recommendations","volume":"8","author":"Baughman","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"9923","key":"10.1016\/j.pupt.2019.101840_bib3","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2019.101840_bib4","first-page":"280","article-title":"The indication for the treatment of sarcoidosis: Wells law","volume":"34","author":"Baughman","year":"2017","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"3","key":"10.1016\/j.pupt.2019.101840_bib5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thx.51.3.238","article-title":"British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment","volume":"51","author":"Gibson","year":"1996","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2019.101840_bib6","first-page":"325","article-title":"Current and emerging pharmacological treatments for sarcoidosis: a review","volume":"7","author":"Beegle","year":"2013","journal-title":"Drug Des. Dev. Ther."},{"issue":"9","key":"10.1016\/j.pupt.2019.101840_bib7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.pupt.2019.101840_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J. Rheumatol."},{"issue":"8","key":"10.1016\/j.pupt.2019.101840_bib9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/rheumatology\/41.8.876","article-title":"Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents","volume":"41","author":"Karim","year":"2002","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.pupt.2019.101840_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/qjmed\/93.1.15","article-title":"The evolving role of mycophenolate mofetil in renal transplantation","volume":"93","author":"Warrens","year":"2000","journal-title":"QJM"},{"issue":"5","key":"10.1016\/j.pupt.2019.101840_bib11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1159\/000345596","article-title":"Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: a retrospective study","volume":"86","author":"Brill","year":"2013","journal-title":"Respiration"},{"issue":"11","key":"10.1016\/j.pupt.2019.101840_bib12","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.rmed.2014.09.013","article-title":"Efficacy of mycophenolate mofetil in sarcoidosis","volume":"108","author":"Hamzeh","year":"2014","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.pupt.2019.101840_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2133.2003.05042.x","article-title":"Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis","volume":"148","author":"Kouba","year":"2003","journal-title":"Br. J. Dermatol."},{"issue":"10 Pt 1","key":"10.1016\/j.pupt.2019.101840_bib14","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.pupt.2019.101840_bib15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1513\/pats.200602-022TK","article-title":"Pulmonary function testing in idiopathic interstitial pneumonias","volume":"3","author":"Martinez","year":"2006","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"5","key":"10.1016\/j.pupt.2019.101840_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MCP.0000000000000091","article-title":"IPF clinical trial design and endpoints","volume":"20","author":"Nathan","year":"2014","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"Suppl 1","key":"10.1016\/j.pupt.2019.101840_bib17","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.pupt.2019.101840_bib18","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"issue":"3","key":"10.1016\/j.pupt.2019.101840_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.12-1728","article-title":"Methotrexate vs azathioprine in second-line therapy of sarcoidosis","volume":"144","author":"Vorselaars","year":"2013","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.pupt.2019.101840_bib20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/ajrccm.184.10.1214","article-title":"Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis","volume":"184","author":"Kamphuis","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.pupt.2019.101840_bib21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"Sahoo","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.pupt.2019.101840_bib22","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1164\/ajrccm.155.5.9154873","article-title":"Pentoxifylline in treatment of sarcoidosis","volume":"155","author":"Zabel","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919301889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553919301889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T15:23:04Z","timestamp":1571844184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553919301889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":22,"alternative-id":["S1094553919301889"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101840","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycophenolate mofetil as an alternative treatment in sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2019.101840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101840"}}